Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Liraglutide stories

May 1, 2026

FDA Moves to Remove GLP-1 Weight Loss Drugs from Compounding List

FDA announced plans to exclude semaglutide, tirzepatide, and liraglutide from its 503B compounding list, citing no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.

May 1, 2026·1 source
00

Top claims

  • ▪The Food and Drug Administration determined there is no clinical need to allow large compounding facilities to make large quantities of medicines from semaglutide
  • ▪Tirzepatide is the ingredient in Eli Lilly's Mounjaro diabetes drug
  • ▪Novo Nordisk and Eli Lilly maintain they have resolved supply shortages that previously justified compounding exemptions

Topics

Eli LillyGLP-1 / Weight-Loss MedicationsWeight managementDrug Policy, Pricing & ApprovalDrug Approval and Clinical TrialsLifestyle, Wellness and NutritionGLP-1 medicationsWeight loss medications & GLP-1 drugsHealthcare PolicyNovo Nordisk

Related entities

TirzepatideSemaglutide